Form 4: Viking Therapeutics CEO Brian Lian Reports Stock Award Vesting and Tax Withholding

Brian Lian, CEO of Viking Therapeutics, reports the vesting of performance-based restricted stock units and subsequent tax withholding.

Summary

• On March 1, 2024, Brian Lian, the President & CEO of Viking Therapeutics, had 221,667 shares of common stock vest as part of a performance restricted stock unit award granted on January 3, 2023.
• This vesting occurred because 33.33% of the award vested upon achieving a non-financial performance goal.
• Also on March 1, 2024, 162,815 shares were withheld by Viking Therapeutics to cover tax obligations related to the vesting of these restricted stock units at a price of $85.22 per share.
• Following these transactions, Lian directly owns 2,198,734 shares of Viking Therapeutics common stock.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing related to stock transactions. It doesn't contain overtly positive or negative information, but the vesting of performance-based units suggests the achievement of company goals.

Positives

• The vesting of performance-based stock units suggests that the company has achieved certain non-financial goals.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.

Stakeholder Impact

• The vesting of stock units could have a minor positive impact on shareholder sentiment, reflecting achievement of performance goals.
• The tax withholding has no material impact on stakeholders.

Key Dates